Why the FDA's focus on breakthrough meds is good news

01/15/2013 | Xconomy

The pharmaceutical industry's focus will shift toward more groundbreaking, innovative medicines because of the Breakthrough Therapy Designation, the FDA's new regulatory incentive structure, Luke Timmerman writes. The emphasis on breakthrough drugs, together with the high number of drug approvals last year, is a positive development for drugmakers and patients, he writes.

View Full Article in:

Xconomy

Published in Briefs:

SmartBrief Job Listings for Health Care

Job Title Company Location
Assistant General Counsel
Cardinal Health
Columbus, OH
Regulatory Affairs Specialist
Stryker
Mahwah, NJ
Sr. Principal OptoMechanical Engineer - 14000008M2
Abbott
San Jose, CA
Senior Director Medical Affairs
Edwards Lifesciences
Irvine, CA
Sr. Principal Electrical Engineer - 14000008LR
Abbott
San Jose, CA